顺铂和每周一次多西他赛联合同期胸部放疗治疗局部晚期Ⅲ期非小细胞肺癌。
Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer.
作者信息
Nakamura Masaru, Koizumi Tomonobu, Hayasaka Munehara, Yasuo Masanori, Tsushima Kenji, Kubo Keishi, Gomi Kotaro, Shikama Naoto
机构信息
First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, Nagano, 390-8621, Japan.
出版信息
Cancer Chemother Pharmacol. 2009 May;63(6):1091-6. doi: 10.1007/s00280-008-0837-0. Epub 2008 Sep 26.
PURPOSE
Our objective was to assess the efficacy and toxicity of concurrent chemoradiotherapy with cisplatin + weekly divided-dose docetaxel in patients with stage III non-small-cell lung cancer (NSCLC).
METHODS
A total of 34 patients aged less than 75 years old with locally advanced stage III NSCLC were enrolled. The patients received intravenous infusions of cisplatin (80 mg/m(2); day 1) and docetaxel (20 mg/m(2); days 1, 8, 15), followed by a week's drug-free interval. Standard concurrent thoracic radiotherapy was given for 6 weeks (2 Gy per fraction; total dose, 60 Gy).
RESULTS
Over Grade 3 neutropenia, esophagitis and pulmonary toxicities were observed in 23.5, 17.6 and 11.8% of the cases, respectively. One complete response and 20 partial responses were obtained, with an objective response rate of 61.8%. The median survival time was 26.4 months (95% CI 16.9--not reached) and the 1- and 3-year survival rates were 76.5 and 41.2%, respectively.
CONCLUSION
Cisplatin + weekly docetaxel with concurrent radiotherapy is a feasible and effective regimen for locally advanced NSCLC.
目的
我们的目标是评估顺铂联合每周分次剂量多西他赛同步放化疗对Ⅲ期非小细胞肺癌（NSCLC）患者的疗效和毒性。
方法
共纳入34例年龄小于75岁的局部晚期Ⅲ期NSCLC患者。患者接受顺铂静脉输注（80mg/m²；第1天）和多西他赛（20mg/m²；第1、8、15天），随后有1周的无药间隔期。给予标准的同步胸部放疗6周（每次分割剂量2Gy；总剂量60Gy）。
结果
分别有23.5%、17.6%和11.8%的病例出现3级以上中性粒细胞减少、食管炎和肺部毒性。获得1例完全缓解和20例部分缓解，客观缓解率为61.8%。中位生存时间为26.4个月（95%CI 16.9 - 未达到），1年和3年生存率分别为76.5%和41.2%。
结论
顺铂联合每周多西他赛同步放疗是局部晚期NSCLC的一种可行且有效的治疗方案。
Zotero 插件